
    
      The study consists of 2 parts:

      Part 1, Phase 1b, is an open-label multiple dose escalation study to evaluate the safety and
      tolerability of KZR-616 in patients with systemic lupus erythematosus (SLE) with and without
      lupus nephritis. The Phase 1b part of this study is fully enrolled and active as of September
      2020.

      Part 2, Phase 2, is an open-label study to evaluate the efficacy and safety of KZR-616 in
      patients with active proliferative lupus nephritis (LN) to assess the number of patients with
      a 50% reduction in UPCR after 24 weeks of weekly SC injections with KZR-616 when compared to
      baseline.
    
  